Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2019, Article ID 5350960, 10 pages
Research Article

Therapeutic Plasma Exchange as Management of Complicated Systemic Lupus Erythematosus and Other Autoimmune Diseases

1Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional (GIRAT), Fundación Valle del Lili and Universidad Icesi, Cali, Colombia
2Blood Bank and Transfusion Service, Fundación Valle del Lili, Cali, Colombia
3Laboratory of Immunology, Fundación Valle del Lili, Cali, Colombia

Correspondence should be addressed to Gabriel J. Tobón; moc.oohay@1nobotg

Received 3 November 2018; Revised 16 January 2019; Accepted 10 February 2019; Published 11 March 2019

Academic Editor: Ricard Cervera

Copyright © 2019 David Aguirre-Valencia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Introduction. Autoimmune diseases include a diverse and complex group of pathologies with a broad clinical spectrum due to the production of autoantibodies, which generates multisystemic compromise. Therapeutic plasma exchange (TPE) is a good additive treatment for immunosuppression due to its action over the autoantibodies. Objectives. To describe the main clinical characteristics and outcomes of patients with systemic lupus erythematosus and other systemic autoimmune diseases managed with TPE. Methodology. This descriptive retrospective study enrolled patients with systemic autoimmune diseases who received TPE. Results. In total, 66 patients with a median age of 33.5 years (24-53 years) were included; the majority were females [n=51 (77.27%)]. Forty (60.61%) patients were diagnosed with systemic lupus erythematosus. In these cases, the main indication for TPE was diffuse alveolar hemorrhage (DAH; n=20, 30.3%) and neurolupus (n=9, 13.6%). No TPE-related deaths occurred, and the main complication was hemorrhage, without significant differences among the four types of TPE solutions used. The overall outcome was improvement in 41 (62.12%) patients. Conclusion. TPE is safe and effective in patients with severe manifestations of autoimmune diseases.